Table 1.

Patient characteristics at time of cancer diagnosis and treatment with abiraterone

	Overall	Alberta	BC	Ontario
No. patients	187	77	51	59
Age
Median age at diagnosis	65	62	66	67
Median age at metastases	70	68	69	72
Median age at abiraterone start	73	70	72	75
Initial presentation
M1 at cancer diagnosis (% within centre)	73 (40%)	30 (41%)	25 (49%)	18 (31%)
Gleason score
≤6	15 (8.0%)*	4	6	5
7	62 (33%)	30	14	18
8	17 (9.0%)	6	5	6
9–10	65 (34%)	18	20	27
Missing	28 (15%)	19	6	3
Risk category
Low	10 (5.3%)	5	2	3
Intermediate	39 (21%)	18	10	11
High	64 (35%)	23	15	26
Metastatic	71 (38%)	30	22	19
Unknown	3 (1.4%)	1	2	0
Extent of metastatic disease pre-abiraterone
Bone only	109 (58%)	50	37	22
Lymph nodes only	33 (18%)	12	5	16
Bone and lymph nodes	19 (10%)	9	6	4
Bone ± lymph nodes + at least one of liver or viscera	3 (1.6%)	1	2	0
Viscera, lung ± lymph nodes	4 (2.1%)	2	1	1
Missing	19 (10%)	3	0	16
ECOG pre-abiraterone
0–1	113 (71%)	60	20	33
2	39 (24%)	13	11	15
3	8 (5%)	3	3	2
missing	27	2	17	9
Chemotherapy pre-abiraterone
Received first line	187 (100%)	77	51	59
Received second line	47 (25%)	15	16	16
Received third line	7 (4%)	1	2	4
PSA pre-abiraterone
Median PSA	132	103	125	160
Median positive PSA doubling time (n = 159)	2.8 months	2.9	2.7	3.0
PSA doubling time not available	n = 6	n = 4	n = 1	n = 1
Proportion of cases with shorter doubling time 0–3 months	75/181 (41%)	31/73 (42%)	26/50 (52%)	27/58 (47%)
Proportion of cases with longer doubling time ≥3 months	84/181 (46%)	30/73 (41%)	20/50 (40%)	25/58 (43%)
Proportion of cases with negative doubling time (non-rising PSA)	22/181 (12%)	12/73 (16%)	4/50 (8%)	6/58 (10%)

BC: British Columbia; ECOG: Eastern Cooperative Oncology Group; PSA: prostate-specific antigen.